Non-prise de greffe, dysfonctionnement du greffon et érythroblastopénie : mise à jour des définitions, outils diagnostiques et prise en charge : recommandation de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) 2021.
Allo-HCT; Allogreffe; Dysfonctionnement du greffon; Erythroblastopenia; Graft failure; Non-prise de greffe; Poor graft failure; Érythroblastopénie; Hematology; Oncology; Radiology, Nuclear Medicine and Imaging; Cancer Research; General Medicine
Abstract :
[en] In this article, we discuss again the definition, the risk factor and guideline to treat the graft failure, the poor graft function and erythrobalstopenia. Graft failure is a severe but rare complication after hematopoietic cell transplantation (HCT). Despite disparity in the literature, we defined this complication and discussed the factor risks and recommendation for treatment based on new studies. Poor graft function is also a more frequent complication after HCT. New studies will soon be available to prove or not the current recommendation suggested in this article based on therapeutics medicine or cellular therapy. Erythroblastopenia, is a rarer complication post HCT. Despite anticipation for a better choice of compatibility donor/recipient, some patients still suffer from this complication.
Disciplines :
Hematology
Author, co-author :
Srour, Micha; Hôpital Huriez, CHRU Lille, maladies du sang, rue Michel-Polonowski, 59000 Lille, France
Fayard, Amandine; CHU de Clermont-Ferrand, service hématologie, 1, rue Lucie- et Raymond-Aubrac, 63003 Clermont-Ferrand, France
Giannotti, Federica; HUG, service hématologie, rue Gabrielle-Perret-Gentil, 4, 1205 Genève, Suisse
Giltat, Aurelien; CHU d'Angers, service hématologie, 4, rue Larrey, 49933 Angers cedex 9, France
Guenounou, Sarah; Institut universitaire du cancer de Toulouse-Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex, France
SCHMITT, Justine ; Centre Hospitalier Universitaire de Liège - CHU > > Pool assistant - biologie clinique
Servais, Sophie ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
Alsuliman, Tamim; AP-HP, hôpital Saint-Antoine, Sorbonne université, service d'hématologie, Paris, France. Electronic address: tamim.alsuliman@aphp.fr
Agha, Ibrahim Yakoub; Université Lille, CHU de Lille, Infininite, Inserm U1286, 59000 Lille, France
Guillerm, Gaelle; Hôpital Morvan, CHRU Brest, service d'hématologie, 2, avenue Foch, 29609 Brest cedex, France
Language :
French
Title :
Non-prise de greffe, dysfonctionnement du greffon et érythroblastopénie : mise à jour des définitions, outils diagnostiques et prise en charge : recommandation de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) 2021.
Alternative titles :
[en] Graft failure, poor graft function erythroblastopenia: Actualization of definitions, diagnosis and treatment: Recommendations of the Francophone Society of Bone Marrow Transplantation and cell therapy (SFGM-TC) 2021.
La SFGM-TC remercie les partenaires industriels pour leur soutien financier qui ont permis la réussite de cette onzième édition des ateliers d'harmonisation des pratiques: ACCORD, ASTELLAS, INCYTE, JAZZ PHARMACEUTICALS, MALLINCKRODT THERAKOS, MEDAC, MSD FRANCE, SANOFI GENZYME.
Dominietto, A., Raiola, A.M., Van Lint, M.T., Lamparelli, T., Gualandi, F., Berisso, G., et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol. 112:1 (2001), 219–227.
Sun, Y.Q., He, G.L., Chang, Y.J., Xu, L.P., Zhang, X.H., Han, W., et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol. 94:10 (2015), 1699–1705.
Cornillon, J., Sicre de Fontbrune, F., Chantepie, S., Coiteux, V., Gauthier, J., Masouridi-Levrat, S., et al. Dysfonctionnement du greffon et érythroblastopénie après allogreffe de cellules souches hématopoïétiques: recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 103:11, Supplement (2016), S248–S254.
Alcazer, V., Peffault de Latour, R., Ader, F., Labussière-Wallet, H., Non-prise de greffe allogénique de cellules souches hématopoïétiques: définition et facteurs de risque identifiés. Bull Cancer 106:6 (2019), 574–583.
McLornan, D.P., Hernandez-Boluda, J.C., Czerw, T., Cross, N., Joachim Deeg, H., Ditschkowski, M., et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 35:9 (2021), 2445–2459.
Tipton, R., Yakoub-Agha, I., Ateliers d'harmonisation des pratiques de la SFGM-TC. Bull Cancer 103:11 (2016), S193–S197.
Valcárcel, D., Sureda, A., Graft Failure. Carreras, E., Dufour, C., Mohty, M., Kröger, N., (eds.) The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies, 7th ed, 2019, Springer, Cham (CH) [cited 2021 Nov 11. Disponible sur: http://www.ncbi.nlm.nih.gov/books/NBK553978/].
2011 Signalement des incidents et effets indésirables après greffe de cellules souches hématopoïétiques [Internet]. [cited 2021 Nov 11]. Available from: https://www.sfgm-tc.com/harmonisation-des-pratiques/55-periode-aigue-de-greffe/146-signalement-des-incidents-et-effets-indesirables-apres-greffe-de-cellules-souches-hematopoietiques.
Nakamura, H., Gress, R.E., Graft rejection by cytolytic T cells. Specificity of the effector mechanism in the rejection of allogeneic marrow. Transplantation. 49:2 (1990), 453–458.
Cluzeau, T., Lambert, J., Raus, N., Dessaux, K., Absi, L., Delbos, F., et al. Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI. Bone Marrow Transplant. 51:5 (2016), 687–691.
Olsson, R.F., Logan, B.R., Chaudhury, S., Zhu, X., Akpek, G., Bolwell, B.J., et al. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 29:8 (2015), 1754–1762.
Masouridi-Levrat, S., Simonetta, F., Chalandon, Y., Immunological basis of bone marrow failure after allogeneic hematopoietic stem cell transplantation. Front Immunol., 7, 2016, 362.
Servais, S., Beguin, Y., Baron, F., Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Emerg Drugs. 18:2 (2013), 173–192.
Dubois, V., Amokrane, K., Beguin, Y., Bruno, B., Chevallier, P., Delbos, F., et al. Greffe de cellules souches hématopoïétiques haplo-identiques avec cyclophosphamide en post-greffe: comment choisir le meilleur donneur en 2019 ? Recommandations de la Société francophone de greffe de mœlle et de thérapie cellulaire (SFGM-TC). Bull Cancer 107:1 (2020), S72–S84.
Ahci, M., Stempelmann, K., Buttkereit, U., Crivello, P., Trilling, M., Heinold, A., et al. Clinical utility of quantitative PCR for chimerism and engraftment monitoring after allogeneic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 23:10 (2017), 1658–1668.
Abraham, A., Hsieh, M., Eapen, M., Fitzhugh, C., Carreras, J., Keesler, D., et al. Relationship between mixed donor–recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant J 23:12 (2017), 2178–2183.
Delie, A., Verlinden, A., Beel, K., Deeren, D., Mazure, D., Baron, F., et al. Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature. Acta Clin Belg. 76:6 (2021), 500–508.
De Vos, J., Baudoux, E., Bay, J.O., Calmels, B., Cras, A., El Cheikh, J., et al. Injections de lymphocytes du donneur (DLI): recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bull Cancer 106:1, Supplement (2019), S35–S39.
Yafour, N., Couturier, M.A., Azarnoush, S., Girault, S., Hermet, E., Masouridi Levrat, S., et al. Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC). Bull Cancer 106:1S (2019), S40–S51.
Andreola, G., Labopin, M., Beelen, D., Chevallier, P., Tabrizi, R., Bosi, A., et al. Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ≥10 years. Bone Marrow Transplant. 50:12 (2015), 1508–1512.
Prata, P.H., Resche-Rigon, M., Blaise, D., Socié, G., Rohrlich, P.S., Milpied, N., et al. Outcomes of salvage haploidentical transplant with post-transplant cyclophosphamide for rescuing graft failure patients: a report on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 25:9 (2019), 1798–1802.
Harada, K., Fuji, S., Seo, S., Kanda, J., Ueki, T., Kimura, F., et al. Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 55:9 (2020), 1784–1795.
Stasia, A., Ghiso, A., Galaverna, F., Raiola, A.M., Gualandi, F., Luchetti, S., et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 20:9 (2014), 1440–1443.
Nakamae, H., Storer, B., Sandmaier, B.M., Maloney, D.G., Davis, C., Corey, L., et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica. 96:12 (2011), 1838–1845.
Alchalby, H., Yunus, D.R., Zabelina, T., Ayuk, F., Kröger, N., Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 51:9 (2016), 1223–1227.
Zhao, Y., Gao, F., Shi, J., Luo, Y., Tan, Y., Lai, X., et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 25:9 (2019), 1898–1907.
Isidori, A., Borin, L., Elli, E., Latagliata, R., Martino, B., Palumbo, G., et al. Iron toxicity – its effect on the bone marrow. Blood Rev. 32:6 (2018), 473–479.
Polverelli, N., Mauff, K., Kröger, N., Robin, M., Beelen, D., Beauvais, D., et al. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: a retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol. 96:1 (2021), 69–79.
Bruno, B., Gooley, T., Sullivan, K.M., Davis, C., Bensinger, W.I., Storb, R., et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 7:3 (2001), 154–162.
Kong, Y., Chang, Y.J., Wang, Y.Z., Chen, Y.H., Han, W., Wang, Y., et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 19:10 (2013), 1465–1473.
Bonin, M., Bornhäuser, M., Concise review: the bone marrow niche as a target of graft versus host disease. Stem Cells. 32:6 (2014), 1420–1428.
Chen, J., Feng, X., Desierto, M.J., Keyvanfar, K., Young, N.S., IFN-γ-mediated hematopoietic cell destruction in murine models of immune-mediated bone marrow failure. Blood. 126:24 (2015), 2621–2631.
Chen, J., Wang, H., Zhou, J., Feng, S., Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation. Ther Adv Hematol., 11, 2020 [2040620720948743].
Cho, S.Y., Lee, D.G., Kim, H.J., Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J Mol Sci., 20(11), 2019, 2666.
Olsson, R., Remberger, M., Schaffer, M., Berggren, D.M., Svahn, B.M., Mattsson, J., et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 48:4 (2013), 537–543.
Deur, C.J., Stone, M.J., Frenkel, E.P., Trace metals in hematopoiesis. Am J Hematol. 11:3 (1981), 309–331.
Maywald, M., Wang, F., Rink, L., Zinc supplementation plays a crucial role in T helper 9 differentiation in allogeneic immune reactions and non-activated T cells. J Trace Elem Med Biol. 50 (2018), 482–488.
Gombart, A.F., Pierre, A., Maggini, S., A review of micronutrients and the immune system – working in harmony to reduce the risk of infection. Nutrients., 12(1), 2020, 236.
Michallet, M., Goldet, K., Sobh, M., Morisset, S., Chelghoum, Y., Thomas, X., et al. Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. Cancer. 119:1 (2013), 107–114.
Jaspers, A., Baron, F., Willems, É., Seidel, L., Hafraoui, K., Vanstraelen, G., et al. Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial. Blood. 124:1 (2014), 33–41.
Bittencourt, H., Rocha, V., Filion, A., Ionescu, I., Herr, A.L., Garnier, F., et al. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transplant. 36:5 (2005), 431–435.
Brissot, E., Alsuliman, T., Gruson, B., Hermet, E., Tirefort, Y., Yakoub-Agha, I., et al. How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: a report of the SFGM-TC (update). Bull Cancer 104:12S (2017), S181–S187.
Larocca, A., Piaggio, G., Podestà, M., Pitto, A., Bruno, B., Di Grazia, C., et al. Boost of CD34 ± selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica. 91:7 (2006), 935–940.
Klyuchnikov, E., El-Cheikh, J., Sputtek, A., Lioznov, M., Calmels, B., Furst, S., et al. CD34 ± selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transplant. 20:3 (2014), 382–386.
Askaa, B., Fischer-Nielsen, A., Vindeløv, L., Haastrup, E.K., Sengeløv, H., Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning. Bone Marrow Transplant. 49:5 (2014), 720–721.
Tanaka, T., Inamoto, Y., Yamashita, T., Fuji, S., Okinaka, K., Kurosawa, S., et al. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 22:5 (2016), 919–924.
Peffault de Latour, R., Chevret, S., Ruggeri, A., Suarez, F., Souchet, L., Michonneau, D., et al. Romiplostim in patients undergoing allogeneic stem cell transplantation: results of a phase I/II multicenter trial. Blood., 128(22), 2016, 65.
Popat, U.R., Ray, G., Bassett, R.L. Jr., Poon, M.Y.C., Valdez, B.C., Konoplev, S., et al. Eltrombopag for post-transplant thrombocytopenia: results of phase II randomized double blind placebo controlled trial. Blood., 126(23), 2015, 738.
Ahmed, S., Bashir, Q., Bassett, R., Poon, M.Y.C., Valdez, B., Konoplev, S., et al. Eltrombopag for post-transplantation thrombocytopenia: results of phase II randomized, double-blind, placebo-controlled trial. Transplant Cell Ther. 27:5 (2021), 430e1–430e7.
Marotta, S., Marano, L., Ricci, P., Cacace, F., Frieri, C., Simeone, L., et al. Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant. 54:8 (2019), 1346–1353.
Sánchez-Guijo, F.M., López-Villar, O., López-Anglada, L., Villarón, E.M., Muntión, S., Díez-Campelo, M., et al. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation. Transfusion 52:5 (2012), 1086–1091.
Liu, X., Wu, M., Peng, Y., Chen, X., Sun, J., Huang, F., et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant. 23:9 (2014), 1087–1098.
Hirokawa, M., Fukuda, T., Ohashi, K., Hidaka, M., Ichinohe, T., Iwato, K., et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant. 19:7 (2013), 1026–1032.
Helbig, G., Stella-Holowiecka, B., Wojnar, J., Krawczyk, M., Krzemien, S., Wojciechowska-Sadus, M., et al. Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies. Ann Hematol. 86:9 (2007), 677–683.
Aung, F.M., Lichtiger, B., Bassett, R., Liu, P., Alousi, A., Bashier, Q., et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 160:6 (2013), 798–805.
Griffith, L.M., McCoy, J.P. Jr., Bolan, C.D., Stroncek, D.F., Pickett, A.C., Linton, G.F., et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 128:5 (2005), 668–675.
Lee, J.H., Lee, K.H., Kim, S., Lee, J.S., Kim, S.H., Kwon, S.W., et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant. 25:2 (2000), 179–184.
Mielcarek, M., Leisenring, W., Torok-Storb, B., Storb, R., Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood. 96:3 (2000), 1150–1156.
Stussi, G., Halter, J., Bucheli, E., Valli, P.V., Seebach, L., Gmür, J., et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica. 94:2 (2009), 239–248.
Crysandt, M., Soysal, H., Jennes, E., Holtick, U., Mrotzek, M., Rehnelt, S., et al. Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility. Eur J Haematol. 107:3 (2021), 324–332.
Paltiel, O., Cournoyer, D., Rybka, W., Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion 33:5 (1993), 418–421.
Santamaría, A., Sureda, A., Martino, R., Domingo-Albós, A., Muñiz-Díaz, E., Brunet, S., Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant. 20:12 (1997), 1105–1107.
Worel, N., Greinix, H., Schneider, B., Kurz, M., Rabitsch, W., Knöbl, P., et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 40:5 (2000), 543–550.
Bolan, C.D., Leitman, S.F., Griffith, L.M., Wesley, R.A., Procter, J.L., Stroncek, D.F., et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 98:6 (2001), 1687–1694.
Ohashi, K., Akiyama, H., Takamoto, S., Tanikawa, S., Sakamaki, H., Onozawa, Y., Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplantation Team. Bone Marrow Transplant. 13:3 (1994), 335–336.
Yamaguchi, M., Sakai, K., Murata, R., Ueda, M., Treatment of pure red cell aplasia after major ABO-incompatible peripheral blood stem cell transplantation by induction of chronic graft-versus-host disease. Bone Marrow Transplant. 30:8 (2002), 539–541.
Dellacasa, C.M., D'Ardia, S., Allione, B., Aydin, S., Tassi, V., Francisci, T., et al. Efficacy of plasmapheresis for the treatment of pure red blood cell aplasia after allogeneic stem cell transplantation. Transfusion 55:12 (2015), 2979–2982.
Verholen, F., Stalder, M., Helg, C., Chalandon, Y., Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol. 73:6 (2004), 441–446.
Zhidong, W., Hongmin, Y., Hengxiang, W., Successful treatment of pure red cell aplasia with a single low dose of rituximab in two patients after major ABO incompatible peripheral blood allogeneic stem cell transplantation. Transfus Med. 22:4 (2012), 302–304.
Maschan, A.A., Skorobogatova, E.V., Balashov, D.N., Pashanov, E.D., Trakhtman, P.E., Schipitzina, I.P., et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant. 30:6 (2002), 405–407.
Helbig, G., Stella-Holowiecka, B., Krawczyk-Kulis, M., Wojnar, J., Markiewicz, M., Wojciechowska-Sadus, M., et al. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Haematologica., 90(Suppl), 2005, ECR33.
Bierman, P.J., Warkentin, P., Hutchins, M.R., Klassen, L.W., Pure red cell aplasia following ABO mismatched marrow transplantation for chronic lymphocytic leukemia: response to antithymocyte globulin. Leuk Lymphoma. 9:1–2 (1993), 169–171.
Varela Gómez, R., Vázquez Vázquez, G., Noriega Concepción, V., Galego García, A., Andón Saavedra, C., Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 11:1 (2018), 44–46.
Poon, L.M., Koh, L.P., Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib. Bone Marrow Transplant. 47:6 (2012), 870–871.
Khan, F., Linden, M.A., Zantek, N.D., Vercellotti, G.M., Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation. Transfus Med. 24:3 (2014), 187–188.
Shahan, J.L., Hildebrandt, G.C., Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma. Transfus Med. 25:5 (2015), 342–344.
Marco-Ayala, J., Gómez-Seguí, I., Sanz, G., Solves, P., Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question. Bone Marrow Transplant. 56:4 (2021), 769–778.
Busca, A., Dellacasa, C., Giaccone, L., Manetta, S., Biale, L., Godio, L., et al. Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 24:8 (2018), 1765–1770.
Gao, Y., Gao, F., Shi, J., Fu, H., Huang, H., Zhao, Y., Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation. J Zhejiang Univ Sci B. 22:8 (2021), 695–700.
Yates, B., Molloy, E., Dulau-Florea, A., Braylan, R., Hogan, L., Hickstein, D.D., et al. Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation. Transfusion 61:4 (2021), 1041–1046.
Jeyaraman, P., Borah, P., Rajput, P., Dayal, N., Pathak, S., Naithani, R., Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia. Blood Cells Mol Dis., 88, 2021, 102464.
Salas, M.Q., Alahmari, A., Lipton, J.H., Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. Eur J Haematol. 104:2 (2020), 145–147.
Chapuy, C.I., Kaufman, R.M., Alyea, E.P., Connors, J.M., Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 379:19 (2018), 1846–1850.
Bathini, S., Holtzman, N.G., Koka, R., Singh, Z., Wilding, E., Zou, Y., et al. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. Am J Hematol. 94:8 (2019), E216–E219.
Handisurya, A., Worel, N., Rabitsch, W., Bojic, M., Pajenda, S., Reindl-Schwaighofer, R., et al. Antigen-specific immunoadsorption with the Glycosorb® ABO immunoadsorption system as a novel treatment modality in pure red cell aplasia following major and bidirectional ABO-incompatible allogeneic hematopoietic stem cell transplantation. Front Med, 7, 2020 [cited 2022 Jul 3. Disponible sur: https://www.frontiersin.org/article/10.3389/fmed.2020.585628].
Longval, T., Galimard, J.E., Leprêtre, A.C., Suarez, F., Amiranoff, D., Cazaux, M., et al. Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol. 193:4 (2021), 814–826.
